Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
BACKGROUND: The OrbiSac device, which was develo‐ped to automate the manufacture of buffy‐coat PLT con‐centrates (BC‐PCs), was evaluated.
STUDY DESIGN AND METHODS: In‐vitro characteristics of BC‐PC preparations using the OrbiSac device were compared with manually prepared BC‐PCs. For standard processing (Std‐PC, n = 20), four BC‐PCs were pooled using 300 mL of PLT AS (PAS) followed by soft‐spin centrifugation and WBC filtration. The OrbiSac pre‐paration (OS‐PC, n = 20) was performed by automated pooling of four BC‐PCs with 300 mL PAS followed by centrifugation and inline WBC filtration. All PCs were stored at 22°C. Samples were withdrawn on Day 1, 5, and 7 evaluating PTL count, blood gas analysis, glucose, lactate, LDH, β‐thromboglobulin, hypotonic shock response, and CD62p expression.
RESULTS: A PLT content of 3.1 ± 0.4 × 1011 (OS‐PCs) versus 2.7 ± 0.5 × 1011 (Std‐PCs, p < 0.05) was found. A CV of 19 percent (Std‐PC) versus 14 percent (OS‐PC) suggests more standardization in the OS group. At Day 7, the Std‐PCs versus OS‐PCs showed a glucose consumption of 1.03 ± 0.32 µmol per 109 PLT versus 0.75 ± 0.25 µmol per 109 PLT (p < 0.001), and a lactate production of 1.50 ± 0.86 µmol per 109 versus 1.11 ± 0.61 µmol per 109 (p < 0.001). The pH (7.00 ± 0.19 vs. 7.23 ± 0.06; p < 0.001), pO2 (45.3 ± 18 vs. 31.3 ± 10.4 mmHg; p < 0.01), and HCO3 levels (4.91 ± 1.49 vs. 7.14 ± 0.95 mmol/L; p < 0.001) suggest a slightly better aerobic metabolism within the OS group. Only small differences in CD62p expression was observed (37.3 ± 12.9% Std‐PC vs. 44.8 ± 6.6% OS‐PC; p < 0.05).
CONCLUSION: The OrbiSac device allows an improved PLT yield without affecting PLT in‐vitro characteristics and may enable an improved consistency in product volume and yield.